Mitsubishi UFJ Asset Management
VKTX icon

Mitsubishi UFJ Asset Management’s Viking Therapeutics VKTX Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$455K Hold
13,974
– – ﹤0.01% 879
2025
Q4 		$495K Hold
13,974
– – ﹤0.01% 883
2025
Q3 		$367K Hold
13,974
– – ﹤0.01% 911
2025
Q2 		$370K Buy
13,974
+3,974
+40% +$105K ﹤0.01% 889
2025
Q1 		$242K Hold
10,000
– – ﹤0.01% 939
2024
Q4 		$429K Buy
+10,000
New +$570K ﹤0.01% 890

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Mitsubishi UFJ Asset Management's VKTX Position: Q1 2026 in Review

Mitsubishi UFJ Asset Management held its Viking Therapeutics (VKTX) position steady in Q1 2026 at 13,974 shares worth $455K. The position accounts for ﹤0.01% of the portfolio, ranked #879.

Mitsubishi UFJ Asset Management first reported a position in VKTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $495K in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Mitsubishi UFJ Asset Management held 13,974 shares of Viking Therapeutics worth $455K as of Q1 2026.
  • Mitsubishi UFJ Asset Management left its Viking Therapeutics share count unchanged in Q1 2026.
  • Viking Therapeutics made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q1 2026, its #879 holding.
  • Mitsubishi UFJ Asset Management first reported a position in Viking Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Mitsubishi UFJ Asset Management's Viking Therapeutics position peaked at $495K in Q4 2025.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q1 2026, filed 12 May 2026.